Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.
about
sameAs
Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvementDiagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation OncologyPatients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US.Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.The role of denosumab for prevention of skeletal-related complications in multiple myeloma.Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents.Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Targeting the Bone Marrow Microenvironment.Bisphosphonates in multiple myeloma: an updated network meta-analysis.Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.Palliative Oncology: Denosumab.[Vertebral metastases of urogenital carcinomas: Diagnosis and conservative therapy].
P2860
Q27011865-4A70932C-5AF5-470F-B2FF-3016C4BE7A8FQ28076646-666FAAEB-C23F-456D-B62A-74EFC764A8EAQ35161962-3BFFE722-7BAC-49B5-91B5-F6DA3D1647C4Q36510928-C9A9F500-CFB4-4463-89FE-3F29E57D58DBQ38115501-0CBAB441-2A27-4454-A81C-675D62DEFC37Q38205856-6A47DA78-16D7-4F25-ABFC-20DB725A8580Q38297692-7F1C4D78-32A3-4286-BBF9-7DE69170E655Q38737970-63A6D9B9-ACEF-4B83-9F62-D3505F5A6305Q38970585-43DD19A5-870A-4CEB-92D3-8C483EC3CC6DQ47290135-277D20A2-0016-471E-AEB7-FF354A14B83DQ47886613-73430A72-CEA7-48A4-80E9-4567563CC52DQ48073269-02AB9130-D967-40EC-B024-C1D3043FD4F0Q53322716-1E8A9782-1BDF-4763-BA3C-C2148059E8EB
P2860
Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Clinical benefit in patients w ...... osumab versus zoledronic acid.
@en
Clinical benefit in patients w ...... osumab versus zoledronic acid.
@nl
type
label
Clinical benefit in patients w ...... osumab versus zoledronic acid.
@en
Clinical benefit in patients w ...... osumab versus zoledronic acid.
@nl
altLabel
Clinical benefit in patients w ...... nosumab versus zoledronic acid
@en
prefLabel
Clinical benefit in patients w ...... osumab versus zoledronic acid.
@en
Clinical benefit in patients w ...... osumab versus zoledronic acid.
@nl
P2093
P2860
P356
P1433
P1476
Clinical benefit in patients w ...... nosumab versus zoledronic acid
@en
P2093
C S Cleeland
Cleeland CS
F Goldwasser
Fallowfield LJ
Goldwasser F
P2860
P2880
P304
P356
10.1093/ANNONC/MDS175
P577
2012-07-31T00:00:00Z
2012-12-01T00:00:00Z